Overview

Pemigatinib After SBRT or Other Minimally Invasive Technique in Advanced iCCA With FGFR2 Fusion/Rearrangements

Status:
Not yet recruiting

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

A Phase II study of pemigatinib after SBRT (Stereotactic Body Radiation Therapy) or other minimally invasive technique as definitive organ preserving therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. The aim of this phase II study is to determine whether pemigatinib is clinically efficious after SRBT or other minimally invasive therapy in iCCA patients harboring FGFR2 fusion/rearrangement and to assess the safety profile to support the continuation of the concept in a large, randomized trial for further development.

Phase:

Phase 2

Details

Lead Sponsor:

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborator:

Incyte Biosciences International Sàrl